Table 1.
Baseline characteristics and disease activity
| MTX monotherapy (n = 284) |
Etanercept monotherapy (n = 284) |
Combination therapy (n = 283) |
|
|---|---|---|---|
| Age in years, mean (s.d.) | 48.7 (13.1) | 48.5 (13.5) | 48.1 (12.7) |
| Female sex, n (%) | 160 (56.3) | 133 (46.8) | 139 (49.1) |
| White race, n (%) | 255 (89.8) | 252 (88.7) | 265 (93.6) |
| Duration of PsA in years, mean (s.d.) [n]a | 3.6 (6.8) [231] | 3.1 (6.0) [222] | 3.0 (6.0) [231] |
| Median (Q1, Q3) [n] | 0.9 (0.1, 3.3) [231] | 0.6 (0.1, 3.0) [222] | 0.5 (0.1, 3.0) [231] |
| Prior use of nonbiologic DMARD, n (%) | 38 (13.4) | 26 (9.2) | 43 (15.2) |
| Body mass index (kg/m2), mean (s.d.) [n] | 30.6 (7.1) [284] | 30.4 (6.6) [283] | 30.0 (6.7) [283] |
| ≤30 kg/m2, n (%) | 146 (51.4) | 153 (53.9) | 160 (56.5) |
| >30 kg/m2, n (%) | 138 (48.6) | 130 (45.8) | 123 (43.5) |
| CRP, mean (s.d.) mg/L [n] | 10.5 (16.3) [284] | 10.7 (15.6) [282] | 8.7 (11.6) [283] |
| mTSS, mean (s.e.) [n] | 2.76 (0.12) [269] | 2.97 (0.13) [273] | 2.70 (0.12) [274] |
| Psoriasis-affected BSA, mean % (s.d.) | 12.7 (18.8) | 10.8 (14.7) | 10.7 (15.6) |
| sPGA, mean (s.d.) [n] | 2.6 (1.1) [281] | 2.6 (1.0) [284] | 2.5 (1.0) [283] |
| Swollen Joint Count (66 joints), mean (s.d.) [n] | 12.9 (9.9) [284] | 11.5 (9.6) [283] | 11.2 (9.1) [282] |
| Tender Joint Count (68 joints), mean (s.d.) [n] | 20.9 (15.0) [284] | 18.8 (14.5) [283] | 20.0 (15.3) [282] |
| Swollen Joint Count (28 joints), mean (s.d.) [n] | 7.7 (5.4) [284] | 6.8 (5.4) [283] | 6.7 (5.0) [282] |
| Tender Joint Count (28 joints), mean (s.d.) [n] | 10.9 (7.4) [284] | 9.5 (7.0) [283] | 9.9 (7.4) [282] |
| Tender Dactylitis Count, mean (s.e.) [n] | 2.3 (0.2) [284] | 2.2 (0.2) [283] | 2.4 (0.3) [282] |
| Leeds Dactylitis Index Score >0 at baseline, n (%) | 98 (34.5) | 96 (33.8) | 90 (31.8) |
| Mean (s.e.) [n] for patients with >0 at baseline | 164.9 (26.9) [98] | 147.6 (20.8) [96] | 138.2 (23.9) [90] |
| Leeds Enthesitis Index Score, mean (s.e.) [n] | 1.5 (0.1) [284] | 1.6 (0.1) [283] | 1.7 (0.1) [282] |
| SPARCC Enthesitis Score >0 at baseline, n (%) | 191 (67.3) | 189 (66.5) | 196 (69.3) |
| Mean (s.e.) [n] for patients with >0 at baseline | 5.7 (0.3) [191] | 5.5 (0.3) [189] | 5.9 (0.3) [196] |
| Physician Global Assessment (0–100), mean (s.d.) [n] | 58.6 (19.4) [284] | 58.3 (18.2) [284] | 58.0 (17.8) [282] |
| Patient Global Assessment (0–100), mean (s.d.) [n] | 60.7 (22.5) [283] | 62.9 (22.1) [284] | 61.0 (20.8) [282] |
| Patient Global Assessment of pain (0–100), mean (s.d.) [n] | 56.1 (21.7) [283] | 56.5 (22.3) [284] | 55.7 (21.6) [282] |
| SF-36 PCS, mean (s.d.) [n] | 35.6 (8.4) [282] | 37.8 (8.4) [284] | 37.4 (9.2) [282] |
| DAS28-CRP, mean (s.d.) [n]; scores range from 2 to 10 | 4.93 (1.11) [283] | 4.80 (1.13) [281] | 4.75 (1.12) [281] |
| CDAI, mean (s.d.) [n]; scores range from 0 to 76 | 30.51 (13.26) [283] | 28.45 (12.89) [283] | 28.55 (12.71) [281] |
| SDAI, mean (s.d.) [n]; scores range from 0 to 86 | 31.56 (13.52) [283] | 29.52 (13.19) [281] | 29.43 (12.90) [281] |
| DAPSA, mean (s.e.) [n]; scores range from 0 to 144 + CRP | 46.5 (1.4) [283] | 43.4 (1.4) [281] | 43.8 (1.4) [281] |
| PASDAS, mean (s.e.) [n]; scores range from 0 to 10 | 6.09 (0.07) [282] | 6.05 (0.07) [279] | 6.04 (0.07) [280] |
[n] is the number of patients analyzed for mean values (if the number is different from the full analysis set). BSA: body surface area; CDAI: Clinical Disease Activity Index; DAPSA: Disease Activity Index for Psoriatic Arthritis; DAS28-CRP: Disease Activity Score (28 joints) using CRP; DMARD: disease-modifying antirheumatic drug; mTSS: van der Heijde modified Total Sharp Score; PASDAS: Psoriatic Arthritis Disease Activity Score; PsA: psoriatic arthritis; Q1: first quartile; Q3: third quartile; SDAI: Simplified Disease Activity Index; SF-36 PCS: Short Form 36 (health survey) Physical Component Summary; SPARCC: Spondyloarthritis Research Consortium of Canada; sPGA: static Physician Global Assessment.